TISI Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
Loading...
Buy TISI now for a near-term rebound/swing setup. The tape is turning mildly bullish (positive/expanding MACD, neutral RSI) while price is holding just above the 14.09 pivot after a -2.50% regular-session drop. With insiders buying aggressively, reaffirmed FY2025 outlook (13% adj. EBITDA growth target), and a fresh $75M Stellex investment supporting expansion/liquidity, the risk/reward favors initiating immediately rather than waiting for a “perfect” entry. Near-term upside levels to watch are 14.64 (R1) then ~14.98 (R2), with the key downside line being 13.54 (S1).
Trend/structure: Mixed-to-slightly bullish. MACD histogram is above zero (0.0852) and expanding, typically supportive of continued upside momentum. RSI(6) at ~56.7 is neutral-to-mildly bullish (not overbought). Moving averages are converging, often a pre-breakout condition rather than a confirmed trend. Levels: Pivot 14.086 is the key “hold” area; current post-market ~14.43 sits below R1 14.636 (first resistance). A clean push above 14.64 opens 14.98 (R2). If price loses 14.09, next supports are 13.54 (S1) and 13.20 (S2). Pattern-based odds: Similar-candlestick analysis suggests a 70% chance of modest gains (+1.61% next day; +0.62% next week; +3.58% next month), which aligns with a small swing-bounce thesis.
Intellectia Proprietary Trading Signals
Latest reported quarter: 2025/Q3. Revenue rose to ~$224.98M (+6.75% YoY), showing steady top-line growth. Margins improved (gross margin ~25.8, +1.57% YoY), indicating better operating quality. Losses narrowed but remain negative: net income improved to about -$12.06M (8.37% improvement YoY) and EPS to -2.68 (6.35% improvement YoY). Overall: improving trend (growth + margin expansion), but not yet profitable.
No analyst rating/price-target change data was provided, so no recent trend can be confirmed. From a ‘Wall Street pros/cons’ lens based on available information: Pros—reaffirmed growth outlook, improving margins, insider buying, and new capital injection. Cons—continued net losses, hedge-fund selling pressure, and CEO transition uncertainty. Politicians/congress: No recent congress trading data available; no politician/influential-figure trades were provided.
